Get the Stockscreener App
0.861
9.67%
0.0759
After Hours:
.87
0.009
+1.05%
Purple Biotech Ltd Adr stock is traded at $0.861, with a volume of 2.36M.
It is up +9.67% in the last 24 hours and up +45.00% over the past month.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
See More
Previous Close:
$0.7851
Open:
$0.78
24h Volume:
2.36M
Relative Volume:
0.31
Market Cap:
$7.78M
Revenue:
-
Net Income/Loss:
$-19.88M
P/E Ratio:
-0.9462
EPS:
-0.91
Net Cash Flow:
$-19.93M
1W Performance:
+44.66%
1M Performance:
+45.00%
6M Performance:
-62.89%
1Y Performance:
-72.32%
1-Day Range:
$0.7659
$0.8799
1-Week Range:
$0.5741
$1.41
52-Week Range:
$0.5326
$13.95
Purple Biotech Ltd Adr Stock (PPBT) Company Profile
Compare PPBT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PPBT
Purple Biotech Ltd Adr
|
0.861 | 7.09M | 0 | -19.88M | -19.93M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Purple Biotech Ltd Adr Stock (PPBT) Latest News
Healthy Upside Potential: VYNE Therapeutics Inc (VYNE) - setenews.com
Purple Biotech stock soars after manufacturing milestone for tri-specific antibody - Investing.com
Dow Surges 250 Points; Verizon Posts Mixed Q3 Results - Benzinga
Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification - GlobeNewswire Inc.
Is Banco Santander S.A. Sponsored ADR stock a top dividend aristocrat candidateEarnings Recap Report & AI Forecast Swing Trade Picks - newser.com
Purple Biotech Enters New ATM Agreement with H.C. Wainwright - The Globe and Mail
Purple Biotech Ltd. enters $2.3M ATM - Investing.com
Purple Biotech (NASDAQ:PPBT) Trading Down 12.3% – Here’s Why - Defense World
Purple Biotech (PPBT) Stock Price, News & Analysis - MarketBeat
Clinical-Stage Cancer Drug Developer Purple Biotech to Present at Major Healthcare Conference - Stock Titan
Purple Biotech (NASDAQ:PPBT) Trading Down 4.9% Following Weak Earnings - Defense World
PPBT’s Stock Market Expedition: Traversing Gains and Losses in 2025 - investchronicle.com
Purple Biotech Highlights Clinical Milestones and Pipeline Progress in H1 2025 - TipRanks
Purple Biotech (NASDAQ:PPBT) Shares Down 2% – Here’s Why - Defense World
Kingswood Wealth Advisors LLC Has $44,000 Holdings in Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT) - Defense World
H.C. Wainwright lifts Purple Biotech stock target to $34 By Investing.com - Investing.com South Africa
H.C. Wainwright lifts Purple Biotech stock target to $34 - Investing.com
Purple Biotech: Advancing Next-Generation Cancer Therapies - roscoeviewjournal.com
Purple Biotech appoints Shai Lankry as new CFO By Investing.com - Investing.com South Africa
Purple Biotech appoints Shai Lankry as new CFO - Investing.com
Best upcoming stock splits and reverse splits 2024 - Investorsobserver
PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy - Nasdaq
Do You Know What To Trade This Month? - StocksToTrade
PPBT stock touches 52-week low at $3.52 amid market challenges - Investing.com
PPBT stock touches 52-week low at $5.89 amid market challenges - Investing.com
What Makes Purple Biotech (PPBT) a New Buy Stock - Yahoo Finance
Purple Biotech stock target cut on trial cohort issue - Investing.com
95 Promising Stocks You Can Currently Buy for Less Than $5 Per Share - GOBankingRates
Purple Biotech (PPBT) Stock Forecast and Price Target 2025 - MarketBeat
Here's Why Purple Biotech Ltd. Sponsored ADR (PPBT) Could be Great Choice for a Bottom Fisher - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Purple Biotech LtdADR (PPBT) News, Articles, Events & Latest Updates - Stocktwits
What is the current Price Target and Forecast for Purple Biotech (PPBT) - Zacks Investment Research
Le 1001 azioni che si sono schiantate sul mercato azionario USA - Scenari Economici
Purple Biotech Stock: Should I invest? - Value The Markets
PPBT Stock Price and Chart — TASE:PPBT - TradingView
Purple Biotech (PPBT) Competitors and Alternatives 2025 - MarketBeat
Purple Biotech Ltd (PPBT) Stock Price, News, Quote & History - Yahoo! Finance Canada
PPBT Stock Price and Chart — NASDAQ:PPBT - TradingView
Salarius Pharmaceuticals (SLRX) Short Interest Ratio and Volume 2025 - MarketBeat
Pre-Market Stock Quote Data - Nasdaq
Can-Fite BioPharma Ltd. (CANF) Stock Price, News, Quote & History - Yahoo
Purple Biotech Ltd Adr Stock (PPBT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):